SHAH ALAM, August 12 – DC Healthcare Holdings Berhad (“DC Healthcare” or the “Group”), a leading provider of aesthetic medical services, successfully made its debut on the ACE Market of Bursa Malaysia Securities Berhad (“Bursa Securities”) today. The stock opened at RM0.40 per share, marking a premium of 60% over the initial public offering (“IPO”) price of RM0.25 per share. DC Healthcare, listed under the stock name “DCHCARE” and stock code “0283,” specializes in non-invasive and minimally invasive procedures.
With 13 aesthetic clinics operating in the central and southern regions of Peninsular Malaysia, the Group offers a range of services, including facial sculpting, body contouring, treatment for skin diseases like psoriasis and eczema, as well as blood test health screening. The IPO raised a total of RM49.81 million, with strategic allocations to support the expansion of DC Healthcare’s clinic network across the northern and southern regions of Peninsular Malaysia. Approximately RM9.44 million will be used for establishing eight new clinics, while RM13.12 million will be allocated for the purchase of medical machinery and equipment.
Additionally, RM6.24 million will go towards repayment of borrowings, and RM17.01 million is earmarked for working capital purposes. The remaining RM4.0 million will cover listing expenses. Chairman of DC Healthcare, Datuk Dr. Mohd Noor Bin Awang, expressed his satisfaction with the listing, stating, “Being the first aesthetic medical services provider listed on Bursa Securities allows DC Healthcare to establish ourselves as a benchmark in the industry.”
Managing Director of DC Healthcare, Dr. Chong Tze Sheng, highlighted the significance of this milestone, emphasizing the Group’s position as a leading provider of aesthetic services in Malaysia. Dr. Chong expressed optimism about leveraging the listing to further enhance shareholder value and consolidate their success. Managing Director of Corporate Finance at M&A Securities Sdn Bhd, Datuk Bill Tan, commended the dedication and hard work of Dr. Chong and the DC Healthcare team.
Tan also underscored the positive prospects for DC Healthcare, considering the growing demand and success of aesthetic services in Malaysia. According to an independent market report attached to DC Healthcare’s prospectus, the Malaysian aesthetic medicine market experienced substantial growth, reaching a value of RM468.8 million in 2022, up from RM366.3 million in 2021. The market is projected to achieve a compound annual growth rate (CAGR) of 18.8% from 2021 to 2027, reaching RM1.03 billion.
The report attributed the rising demand for aesthetic medical services to factors such as increased disposable income among Malaysians due to ongoing economic recovery and a growing ageing population. Furthermore, the influence of social media culture has significantly reduced the stigma associated with aesthetic procedures, contributing to the industry’s growth.
